• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ikena Oncology Reports Second Quarter 2024 Financial Results

    8/8/24 4:15:00 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IKNA alert in real time by email

    BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities.

    Pipeline Updates

    • Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period
      • Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood
    • In May 2024, the Company announced the discontinuation of the IK-930 clinical program

    Corporate Updates

    • In May 2024, the Company announced it was evaluating a range of potential strategic options to maximize shareholder value, and implemented a 53% workforce reduction
    • In July 2024, the Company announced the appointment of Jotin Marango to serve as Chief Operating Officer, in addition to his roles as the Company's Chief Financial Officer and Head of Corporate Development

    Financial Results for the Quarter Ended June 30, 2024

    As of June 30, 2024, the Company had cash, cash equivalents, and marketable securities of $145.4 million.

    Research and development expenses for the three months ended June 30, 2024 and 2023 were $9.8 million and $15.2 million, respectively.

    General and administrative expenses for the three months ended June 30, 2024 and 2023 were $5.3 million and $5.3 million, respectively.

    Restructuring and other costs for the three months ended June 30, 2024 were $0.7 million.

    The Company reported a net loss for the three months ended June 30, 2024 and 2023 of $13.7 million and $17.1 million, respectively.

    About Ikena Oncology

    Ikena Oncology® develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Ikena aims to utilize its depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient. To learn more, visit www.ikenaoncology.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding: the timing and advancement of the targeted oncology program that the Company is pursuing; the Company's expectations regarding the therapeutic benefit of its targeted oncology programs; and the Company's ability to identify any potential strategic options and maximize shareholder value. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing, progress, results, and cost of the Company's current research and development programs and clinical trials; the Company's ability to identify, implement and realize the anticipated benefits from any strategic transaction; the Company's ability to obtain funding for its operations necessary to complete further development and commercialization of its product candidates; the Company's ability to obtain and maintain regulatory approval of its product candidates; the implementation of the Company's business model, and strategic plans for its business and product candidates; and other factors discussed in the "Risk Factors" section of Ikena's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, which is on file with the Securities and Exchange Commission (SEC), as updated by any subsequent SEC filings. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.

    Investor and Media Contact:

    Rebecca Cohen

    [email protected]

     
    Selected Financial Information
    (in thousands, except share and per share data)
    (unaudited)
        
    Selected Statement of Operations Items: Three Months Ended June 30, 2024 Six Months Ended June 30, 2024
      2024   2023   2024   2023 
    Collaboration revenue $—  $2,004  $—  $7,316 
    Operating expenses:        
    Research and development  9,832   15,172   19,477   30,723 
    General and administrative  5,308   5,322   11,307   10,598 
    Restructuring and other charges  683   —   3,265   — 
    Total operating expenses  15,823   20,494   34,049   41,321 
    Loss from operations  (15,823)  (18,490)  (34,049)  (34,005)
    Other income (expense)  2,155   1,375   4,262   2,671 
    Loss before income taxes  (13,668)  (17,115)  (29,787)  (31,334)
    Income tax expense  (62)  —   (89)  — 
    Net loss $(13,730) $(17,115) $(29,876) $(31,334)
    Net loss per share:        
    Net loss per share- basic and diluted $(0.28) $(0.44) $(0.62) $(0.83)
    Weighted-average common shares outstanding, basic and diluted  48,258,111   39,292,710   48,258,111   37,783,486 



    Selected Balance Sheet Items: June 30,

    2024
     December 31,

    2023
    Cash, cash equivalents, and marketable securities $145,419  $175,465 
    Total assets $157,485  $192,092 
    Total liabilities $14,626  $22,335 
    Total stockholders' equity $142,859  $169,757 


    Primary Logo

    Get the next $IKNA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IKNA

    DatePrice TargetRatingAnalyst
    5/29/2024$8.00 → $2.00Outperform → Neutral
    Wedbush
    9/22/2023$11.00Outperform
    Wedbush
    5/4/2023$18.00Buy
    H.C. Wainwright
    12/23/2021$25.00Buy
    HC Wainwright & Co.
    8/13/2021$30.00 → $27.00Outperform
    Credit Suisse
    More analyst ratings

    $IKNA
    SEC Filings

    See more
    • Ikena Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Ikena Oncology, Inc. (0001835579) (Filer)

      7/25/25 12:23:39 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Ikena Oncology Inc.

      10-Q - Ikena Oncology, Inc. (0001835579) (Filer)

      7/24/25 5:17:25 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Ikena Oncology Inc.

      8-K - Ikena Oncology, Inc. (0001835579) (Filer)

      7/24/25 9:18:39 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ikena Oncology downgraded by Wedbush with a new price target

      Wedbush downgraded Ikena Oncology from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously

      5/29/24 7:45:06 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Ikena Oncology with a new price target

      Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00

      9/22/23 7:17:31 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright resumed coverage on Ikena Oncology with a new price target

      H.C. Wainwright resumed coverage of Ikena Oncology with a rating of Buy and set a new price target of $18.00

      5/4/23 8:00:07 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

      BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

      7/23/25 9:00:00 AM ET
      $IKNA
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ikena Oncology Reports Second Quarter 2024 Financial Results

      BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood In May 2024, the Company announced the discontinuation of the IK-930 clinical program Corporate Updates In

      8/8/24 4:15:00 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ikena Oncology Inc.

      SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

      11/14/24 5:05:17 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ikena Oncology Inc.

      SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

      11/13/24 4:05:14 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ikena Oncology Inc. (Amendment)

      SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

      3/11/24 8:19:04 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Financials

    Live finance-specific insights

    See more
    • Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

      Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena's acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr's assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a com

      8/7/23 7:00:00 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

      The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) --  Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflamma

      7/25/25 11:00:00 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

      BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

      7/23/25 9:00:00 AM ET
      $IKNA
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

      Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena's stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals ("Inmagene"). The merger proposal allows for the issuance of shares of Ikena's common stock both to the shareholders of Inmagene and to the investors of the financing concurrent to the merger. Following th

      7/15/25 4:15:00 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wooster Richard

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:08 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dukes Iain D.

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:06 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Formela Jean Francois

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:09 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care